Checkpoints controlling the induction of B cell mediated autoimmunity in human autoimmune diseases
- PMID: 33152108
- DOI: 10.1002/eji.202048820
Checkpoints controlling the induction of B cell mediated autoimmunity in human autoimmune diseases
Abstract
B cell targeting therapies are effective in various autoimmune diseases, among others rheumatoid arthritis, pemphigus vulgaris, and systemic lupus erythematosus. Given these successes, it is evident that B cells are central orchestrators in the processes leading to the signs and symptoms hallmarking many human autoimmune diseases. The pathways provoking the generation of such autoreactive B cells or mechanisms preventing their induction in health are, however, poorly explored. Nevertheless, such information is crucial for the development of preventative/curative interventions aiming to permanently deplete- or prohibit the emergence of autoreactive B cells. Hence, this review will focus on how B cell tolerance might be breached, and which checkpoints are at play preventing the arousal of autoreactive B cells in human. Especially antigen presentation by follicular dendritic cells, somatic hypermutation, and cross-reactivity to the microbiome/environment could operate as actors playing pivotal roles in the induction of B cell-mediated humoral autoimmunity. Moreover, we highlight the human autoimmune disease rheumatoid arthritis as a prototype where autoreactive B cells combine several mechanisms to overcome peripheral B cell checkpoints.
Keywords: autoimmunity; cross presentation/priming; regulatory T cells; rheumatology; tolerance.
© 2020 Wiley-VCH GmbH.
Similar articles
-
Checkpoints in lymphocyte development and autoimmune disease.Nat Immunol. 2010 Jan;11(1):14-20. doi: 10.1038/ni.1794. Epub 2009 Dec 17. Nat Immunol. 2010. PMID: 20016505 Review.
-
Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies.Immunol Rev. 2019 Nov;292(1):90-101. doi: 10.1111/imr.12821. Epub 2019 Nov 12. Immunol Rev. 2019. PMID: 31721234 Free PMC article. Review.
-
The role of B lymphocytes in the progression from autoimmunity to autoimmune disease.Clin Immunol. 2013 Jan;146(1):34-45. doi: 10.1016/j.clim.2012.10.005. Epub 2012 Oct 22. Clin Immunol. 2013. PMID: 23202542 Review.
-
B-cell tolerance checkpoints in health and autoimmunity.Curr Opin Immunol. 2008 Dec;20(6):632-8. doi: 10.1016/j.coi.2008.09.001. Epub 2008 Oct 25. Curr Opin Immunol. 2008. PMID: 18848883
-
B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells.Cells. 2021 May 13;10(5):1190. doi: 10.3390/cells10051190. Cells. 2021. PMID: 34068035 Free PMC article. Review.
Cited by
-
T Cells, Interleukin-2 and Systemic Lupus Erythematosus-From Pathophysiology to Therapy.Cells. 2022 Mar 12;11(6):980. doi: 10.3390/cells11060980. Cells. 2022. PMID: 35326431 Free PMC article. Review.
-
Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation.Sci Adv. 2022 Feb 11;8(6):eabm1759. doi: 10.1126/sciadv.abm1759. Epub 2022 Feb 9. Sci Adv. 2022. PMID: 35138894 Free PMC article.
-
Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.Blood Adv. 2023 Jan 10;7(1):122-130. doi: 10.1182/bloodadvances.2022008071. Blood Adv. 2023. PMID: 35947142 Free PMC article.
-
B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?Front Med (Lausanne). 2022 Apr 4;9:851532. doi: 10.3389/fmed.2022.851532. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35449805 Free PMC article. Review.
-
CLL stereotyped B-cell receptor immunoglobulin sequences are recurrent in the B-cell repertoire of healthy individuals: Apparent lack of central and early peripheral tolerance censoring.Front Oncol. 2023 Mar 17;13:1112879. doi: 10.3389/fonc.2023.1112879. eCollection 2023. Front Oncol. 2023. PMID: 37007084 Free PMC article.
References
-
- Edwards, J. C. and Cambridge, G., Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 2005. 44: 151-156.
-
- Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M. and Shaw, T., Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. N. Engl. J. Med. 2004. 350: 2572-2581.
-
- Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F. et al., First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet North Am. Ed. 2017. 389: 2031-2040.
-
- Musette, P. and Bouaziz, J. D., B cell modulation strategies in autoimmune diseases: new concepts. Front. Immunol. 2018..
-
- Hampe, C. S., B Cell in Autoimmune Diseases. Scientifica (Cairo) 2012. 2012.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical